Cytek Biosciences, Inc.
CTKB
$5.36
-$0.03-0.56%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.18% | 63.53% | 2.23% | 50.44% | 28.98% |
| Total Depreciation and Amortization | 14.73% | 15.09% | 10.37% | 13.65% | 17.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.27% | -54.19% | -37.41% | -29.46% | 23.66% |
| Change in Net Operating Assets | -172.74% | -99.65% | 172.00% | 173.39% | 182.16% |
| Cash from Operations | -105.83% | -1.51% | 233.81% | 380.57% | 1,576.55% |
| Capital Expenditure | 3.73% | 2.67% | 19.17% | 24.16% | 57.32% |
| Sale of Property, Plant, and Equipment | 155.67% | 252.63% | -- | -- | -- |
| Cash Acquisitions | -99.58% | -98.73% | -98.73% | 98.96% | 99.47% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -442.69% | -211.77% | -186.03% | -79.68% | 111.55% |
| Cash from Investing | -640.41% | -225.92% | -197.89% | 11.63% | 105.47% |
| Total Debt Issued | 397.92% | 249.75% | 149.43% | -- | -53.20% |
| Total Debt Repaid | -248.39% | -248.74% | -246.95% | 1.42% | -17.47% |
| Issuance of Common Stock | -42.90% | -47.54% | -37.89% | -18.18% | 1.07% |
| Repurchase of Common Stock | 54.64% | 25.41% | 26.62% | 50.27% | -409.22% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 65.50% | 29.09% | 27.91% | 62.16% | -991.63% |
| Foreign Exchange rate Adjustments | -90.19% | -134.16% | 20.07% | 413.63% | 234.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5,105.35% | -320.92% | -300.95% | 47.76% | 99.25% |